› $4.85 Billion settlement in drug case
For many smokers trying to kick their addiction, the latest news about the dangers of Pfizer’s smoking-cessation drug Chantix presents as a damned if you do, damned if you don’t dilemma. The U.S. Food and Drug Administration issued an alert yesterday, warning that use of the popular drug could lead to increased risk of heart attack and other adverse cardiovascular events.
A senior scientist working for the non-profit Institute for Safe Medicine Practices has discovered that Chantix is a much more dangerous drug than has been officially acknowledged after finding hundreds of serious adverse reactions were reported to the FDA by manufacturer Pfizer Inc. through improper channels.
It’s difficult for some coffee drinkers to imagine life before decaf. Pretty soon it may be difficult for some smokers to imagine life before de-nic. A New York company called 22nd Century Limited recently announced that it is making progress in its development of a very low nicotine (VLN) cigarette that uses a specially engineered and proprietary form of tobacco.
The U.S. Food and Drug Administration announced today that it will require drug manufacturers to put boxed warnings on the product labeling for Chantix (varenicline) and Zyban (bupropion hydrochloride, otherwise called Wellbutrin when prescribed as an antidepressant). Both Chantix and Zyban, commonly prescribed to patients as smoking cessation aids, have been linked to serious behavioral changes and other symptoms. Agitation, hostility, depression, and suicidal thoughts and actions are possible side effects that users should be keenly aware of, the FDA warns.
CNN reports that Pfizer is thinking about launching a clinical test to determine if Chantix can help prevent smokers from having heart attacks. Considering all the negative publicity that has surrounded the drug over the last one and a half years, it’s understandable that Pfizer would want to invest a good deal of time and money in finding some benefit … even if they locate just one slightly dubious side effect, such as a reduced risk of heart attack in people who have quit smoking.
Health Canada has received 818 reports of adverse side effects caused by the smoking cessation drug Chantix (marketed in Canada and elsewhere as Champix) since it first became available to Canadians nearly two years ago. The majority of complaints concerned psychiatric problems. Chantix is known to cause or exacerbate a spectrum of psychiatric and physical reactions, including moodiness, depression, violent behavior, lack of sleep, blackouts, and suicidal thought and actions.
Chantix has to be one of the most bipolar prescription drugs ever created. Every day, a search for the latest Chantix news digs up blogs written by fans of the smoking cessation drug, who often tout it as a miracle or a blessing in their struggle to become nonsmokers. Yet other users liken it to a nightmare or a curse, citing wild mood swings, disturbing dreams, and uncharacteristic thoughts of suicide.
Many medical researchers find little surprise that Chantix has been linked to higher than normal rates of depression and suicide. Varenicline (the chemical name of Pfizer’s smoking cessation drug) goes to work directly in the brain by targeting certain receptors and simulating that feeling of having already smoked – that “full” feeling smokers feel after they’ve lit up one or two. Other pharmaceuticals that go to work directly in the brain include antidepressants, some of which have also been linked to behavioral problems and suicide.
According to a report in today’s Stars & Stripes, a daily newspaper published for the U.S. military, Department of Defense (DoD) civilians, contractors and their families, the anti-smoking medication Chantix (varenicline) has been pulled from at least one military pharmacy following reports of serious adverse reactions.
George J. Lisicki, a Vietnam combat veteran and national commander for the Veterans of Foreign Wars (VFW), had harsh words for the Veterans Administration (VA) today.
“Those in the VA who failed to properly notify America’s veterans that their medication could produce fatal side effects must resign their positions,” Lisicki said. “If not, then the VA secretary must take decisive action to terminate their employment.”
